Pharmacoeconomic review report : Risankizumab (Skyrizi) (AbbVie)

Pharmacoeconomic review report Risankizumab (Skyrizi) (AbbVie)

Risankizumab is a humanized immunoglobulin G1 monoclonal antibody1 with an indication for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Risankizumab is available as a solution for injection in a single-use, pre-fille...

Full description

Bibliographic Details
Main Author: Canadian Agency for Drugs and Technologies in Health (author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Format: eBook
Language:Inglés
Published: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health 2019.
Subjects:
Cost effectiveness.
See on Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820268206719
Table of Contents:
  • Abbreviations
  • Executive Summary
  • Background
  • Summary of Identified Limitations and Key Results
  • Conclusions
  • Information on the Pharmacoeconomic Submission
  • Summary of the Manufacturer's PE Submission
  • Manufacturer's Base Case
  • Summary of Manufacturer's Sensitivity Analyses
  • Limitations of Manufacturer's Submission
  • CADTH Common Drug Review Reanalyses
  • Patient Input
  • Issues for Consideration
  • Conclusions
  • Appendix 1. Cost Comparison
  • Appendix 2. Additional Information
  • Appendix 3. Summary of Other HTA Reviews of Drug
  • Appendix 4. Reviewer Worksheets
  • References.

Similar Items